China Pharma Holdings, Inc.
CPHI · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.25 | 0.24 | -0.19 | -15.64 |
| FCF Yield | -1.86% | -1.11% | -0.32% | -0.06% |
| EV / EBITDA | -22.23 | 7,982.07 | -309.25 | 4,865.44 |
| Quality | ||||
| ROIC | -38.02% | -21.45% | -66.16% | -18.69% |
| Gross Margin | -43.84% | -4.01% | -6.09% | 3.62% |
| Cash Conversion Ratio | 0.10 | 0.23 | 0.10 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -17.63% | -10.08% | -9.31% | -4.08% |
| Free Cash Flow Growth | -6.59% | 12.36% | -17.97% | 24.37% |
| Safety | ||||
| Net Debt / EBITDA | -1.51 | 380.53 | -8.03 | 33.12 |
| Interest Coverage | -29.77 | -8.25 | -8.17 | -5.75 |
| Efficiency | ||||
| Inventory Turnover | 2.87 | 1.95 | 2.92 | 2.78 |
| Cash Conversion Cycle | 137.01 | 176.36 | 117.74 | 126.40 |